Skip to content
All resources

Selank

What Is Selank? The Tuftsin-Derived Heptapeptide Explained

CL

By

· 10 min read

A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.

On this page · 8 sections
  1. Where does Selank come from?
  2. What is Selank, chemically?
  3. How is Selank proposed to work?
  4. What has Selank been studied in, and how far did each line get?
  5. What is Selank's regulatory status?
  6. What is Selank commonly confused with?
  7. How should a researcher read the Selank literature?
  8. Frequently asked questions

Selank is a synthetic seven-amino-acid peptide, Thr-Lys-Pro-Arg-Pro-Gly-Pro, developed at the Institute of Molecular Genetics of the Russian Academy of Sciences in Moscow. Its first four residues are tuftsin, a natural immune peptide cleaved from immunoglobulin G; the last three are a Pro-Gly-Pro tail. It is a registered medicine in Russia, where it is used in the anxiety category, and is approved nowhere else. Most of its literature is Russian, small, and either animal work or clinical studies that have not been replicated outside Russia.

Signalling molecules crossing a synapse between two neurons
Illustration: a synapse, the level at which Selank's proposed mechanisms sit.

Where does Selank come from?

From an immune peptide, which is the unusual part. Tuftsin was described by Victor Najjar and colleagues in the early 1970s as a "phagocytosis-stimulating tetrapeptide" (PMID 4116440). Najjar later recounted how it was found: a short peptide was responsible for the whole stimulating effect of a fraction of gamma-globulin on neutrophils. It was released from the parent antibody by two enzymes, one in the spleen and one on the surface of the phagocyte. It was isolated and sequenced as Thr-Lys-Pro-Arg, and people with a mutant form of it had frequent severe infections (PMID 6370072). Nishioka and colleagues synthesised it in 1973 (PMID 4710594).

Tuftsin itself is short-lived, and a large literature of tuftsin analogues followed, reviewed by Siebert and colleagues (PMID 28745220). Selank is one of them. The Moscow group, whose papers include the chemist Nikolai Myasoedov, added the tripeptide Pro-Gly-Pro to tuftsin's C-terminus. Pro-Gly-Pro belongs to a family of proline-rich "glyprolines" that the same researchers characterised among the most stable regulatory peptides they studied (PMID 14682258), and the same tail appears on Semax.

That origin explains why Selank's literature has two halves that rarely meet: one about anxiety and brain chemistry, and one about immune gene expression and cytokines.

What is Selank, chemically?

PropertySelank
SequenceThr-Lys-Pro-Arg-Pro-Gly-Pro (TKPRPGP)
Length7 amino acids (a heptapeptide)
Built fromTuftsin (TKPR) plus a Pro-Gly-Pro tail
Developed atInstitute of Molecular Genetics, Russian Academy of Sciences, Moscow
Other namesTP-7 (in the FDA's compounding listing)
Regulatory statusRegistered in Russia; not approved in Canada, the US or the EU
Sister compoundSemax, an ACTH(4-10) analogue with the same Pro-Gly-Pro tail

How is Selank proposed to work?

Several mechanisms have been proposed, each resting on one or two papers, mostly from the same institute.

Slowing enkephalin breakdown. Zozulya and colleagues reported that patients with generalised anxiety disorder had a shortened enkephalin half-life in blood, and that Selank inhibited the enzymes that break down plasma enkephalin, with an IC50 of 15 µM. It was more potent than the reference peptidase inhibitors bacitracin and puromycin (PMID 11550013). Enkephalins are endogenous opioid peptides, so this proposes an indirect route to anxiety-related biology. A concentration of 15 µM is high for a pharmacological effect, and the measurement was in plasma, not brain.

Modulating the GABA-A receptor. Vyunova and colleagues used radioligand binding on brain membranes and reported that Selank changed GABA binding in the manner of a positive allosteric modulator. They also found it altered the modulatory activity of diazepam and olanzapine, apparently through a separate binding site (PMID 30255741). That is a binding-assay result from the developing institute, not a demonstration of what happens in a living brain.

Changing gene expression. Volkova and colleagues reported that Selank changed the expression of 45 of 84 neurotransmission-related genes in rat frontal cortex an hour after administration, with changes that correlated with those after GABA (PMID 26924987). On the immune side, Kolomin and colleagues reported changes in 34 of 84 inflammation-related genes in mouse spleen (PMID 21609736).

How these fit together, if they do, has not been worked out. The stress-axis and learning claims are examined in their own articles: Selank and the stress response shows that none of the commonly cited papers measured cortisol or ACTH, and Selank and cognitive performance reads the avoidance-learning and BDNF papers closely.

What has Selank been studied in, and how far did each line get?

Research areaWhat was examinedEvidence stageDeep-dive
AnxietyComparison with medazepam in 62 patients with generalised anxiety disorder or neurastheniaHuman, Russian, not replicated elsewhereThis page
Enkephalin metabolismPlasma enzyme activity in patients; enzyme inhibition in vitroHuman samples and in vitroThis page
GABA signallingReceptor binding; gene expression in rat cortex and nerve cellsCell and animalstress response
Learning and memoryConditioned avoidance in rats; hippocampal BDNFAnimalcognitive performance
Immune and cytokine effectsSpleen gene expression in mice; cytokine balance in patientsAnimal and small humanThis page
InfluenzaVirus in cell culture and infected miceCell and animalThis page

The anxiety study. The clinical claim rests largely on Russian-language work. In the study most often cited, Zozulia and colleagues compared Selank in 30 patients with medazepam, a benzodiazepine, in 32, using Hamilton, Zung and clinical global impression scales. They reported similar anxiolytic effects for both, with additional "antiasthenic and psychostimulant" effects for Selank (PMID 18454096). The English abstract does not describe randomisation, blinding or a placebo group, and the full text is in Russian. A comparison with an active drug and no placebo cannot separate the effect of either drug from natural improvement or expectation.

Immune work. Uchakina and colleagues reported changes in the balance of Th1 and Th2 cytokines in the blood of patients with generalised anxiety disorder or neurasthenia who received Selank for 14 days, and effects on IL-6 gene expression in blood cells in culture (PMID 18577961). Ershov and colleagues reported activity against an influenza A strain in cell culture and in mice, with increased interferon-α gene expression (PMID 19882898). These results connect back to tuftsin's immune role, but they are small, unreplicated and published mainly in Russian journals.

What is Selank's regulatory status?

  • Russia. Registered as a medicine, in the anxiety category.
  • Everywhere else. Not approved by Health Canada, the FDA or the EMA for any indication. A search of ClinicalTrials.gov for Selank in October 2026 found no registered trials of it.
  • US compounding. The FDA lists "selank acetate (TP-7)" among bulk substances nominated for compounding that may present significant safety risks. It cites possible immunogenicity and says it lacks enough information to know whether the drug would cause harm.
  • Canada. Not an authorised drug. Sold here as a research chemical for laboratory use only.

Registration in one country means a regulator there accepted a dossier for a named indication and a manufactured product. It does not transfer to other jurisdictions or to research-grade material.

What is Selank commonly confused with?

Semax. The sister compound from the same institute, with the same Pro-Gly-Pro tail but a different parent: a fragment of ACTH, not tuftsin. The comparison is in Semax vs Selank. Semax's modified form is discussed in N-acetyl Semax amidate vs Semax.

Tuftsin. Selank contains tuftsin's sequence but is a different molecule with its own, much smaller literature. Findings for tuftsin do not transfer automatically.

A benzodiazepine. Selank is often compared to benzodiazepines because the Russian clinical work used one as the comparator. The proposed mechanisms, from enkephalinase inhibition to allosteric binding to gene expression, are not the same as a benzodiazepine's direct action at the GABA-A receptor.

An immune peptide like Thymosin Alpha-1. Both have immune literatures, but they are unrelated sequences; see what is Thymosin Alpha-1. Other short fragment-derived peptides on this site, such as KPV, show the same pattern: a fragment of a natural molecule, studied for a narrower purpose than its parent.

How should a researcher read the Selank literature?

Ask where each paper comes from and in what language. Most Selank research was produced by the Institute of Molecular Genetics and collaborating Moscow centres, and much of the clinical work has only an English abstract. Ask whether a clinical study had a placebo arm and blinding. And ask whether a mechanism was measured in a living animal or inferred from a binding assay or an enzyme test. How to read a peptide study sets out the general checklist.

Nothing here is medical, dosing, or therapeutic guidance.

Supplied here for laboratory use: Selank. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.

Frequently asked questions

What is Selank made of? Seven amino acids: threonine, lysine, proline, arginine, proline, glycine, proline. The first four are tuftsin, a natural immune peptide cut from immunoglobulin G. The last three are a Pro-Gly-Pro tail from a family of peptides its Moscow developers describe as unusually stable. The same tail appears on Semax.

Is Selank approved anywhere? It is registered as a medicine in Russia, in the anxiety category. It is not approved by Health Canada, the FDA or the EMA, and no trial of it is registered on ClinicalTrials.gov. The FDA lists Selank acetate among compounding substances that may present significant safety risks, citing a lack of safety information.

Is Selank a benzodiazepine? No. It is a peptide, and its proposed mechanisms differ. One binding study reported that it modulates GABA binding allosterically through a site that seems separate from diazepam's. Other work proposes slowed enkephalin breakdown or changes in gene expression. The benzodiazepine comparison comes mainly from Russian clinical studies that used medazepam as the comparator drug.

How strong is the human evidence for Selank? Thin. The most cited study compared Selank with medazepam in 62 patients and reported similar anxiolytic effects. Its English abstract does not describe randomisation, blinding or a placebo group, and the work has not been replicated outside Russia. The rest of the literature is animal, cell-culture and binding-assay research.

What is tuftsin? A four-residue peptide, Thr-Lys-Pro-Arg, released from immunoglobulin G by two enzymes and described in the early 1970s as stimulating phagocytic cells. People with a mutant form were reported to have frequent severe infections. Selank is one of many synthetic tuftsin analogues, most of them studied for anti-tumour, anti-inflammatory, antimicrobial or antiviral activity rather than anxiety.

Selected Research References

  1. Najjar VA, Constantopoulos A. A new phagocytosis-stimulating tetrapeptide hormone, tuftsin, and its role in disease. Journal of the Reticuloendothelial Society. 1972;12(2):197-215. pubmed.ncbi.nlm.nih.gov/4116440
  2. Najjar VA. Tuftsin, a natural activator of phagocyte cells: an overview. Annals of the New York Academy of Sciences. 1983;419:1-11. pubmed.ncbi.nlm.nih.gov/6370072
  3. Zozulya AA, Kost NV, Sokolov OY, et al. The inhibitory effect of Selank on enkephalin-degrading enzymes as a possible mechanism of its anxiolytic activity. Bulletin of Experimental Biology and Medicine. 2001;131(4):315-317. pubmed.ncbi.nlm.nih.gov/11550013
  4. Zozulia AA, Neznamov GG, Siuniakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(4):38-48. pubmed.ncbi.nlm.nih.gov/18454096
  5. Vyunova TV, Andreeva L, Shevchenko K, Myasoedov N. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein and Peptide Letters. 2018;25(10):914-923. pubmed.ncbi.nlm.nih.gov/30255741
  6. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in Pharmacology. 2016;7:31. pubmed.ncbi.nlm.nih.gov/26924987
  7. Kolomin T, Shadrina M, Andreeva L, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regulatory Peptides. 2011;170(1-3):18-23. pubmed.ncbi.nlm.nih.gov/21609736
  8. Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2008;108(5):71-75. pubmed.ncbi.nlm.nih.gov/18577961

All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.